The pineal hormone melatonin, which studies have shown to be
a potent immunomodulator and whose primary function is the regulation of
sleep-wake cycles, possesses an incredibly broad spectrum of anti-inflammatory,
antioxidant, and antiapoptotic activity. It may also have potential
cytoprotective, neuroprotective, nephroprotective, cardioprotective,
anti-hypertensive, anti-nociceptive, and other protective effects. In this
article and brief review, we examine the cutting-edge of the prospective use of
the chronobiotic drug melatonin in the treatment of COVID-19 disease as well as
its potential involvement in maintaining neurocognitive health and treating
SARS-2-CoV infection. There is motivation for investigating the use of
melatonin in the potential amelioration of some of the newly identified
pathological neurocognitive sequelae, particularly the cognitive impairment
that is increasingly manifest as part of the cluster known as post-acute
sequelae of COVID-19 (PASC), aka "Long COVID," given the recognized
dysregulated neuro-inflammatory processes that underlie SARS-CoV-2 infection.
In the process, we review clinical evidence of benefit in these areas,
suggesting the strong promise that melatonin appears to offer, with excellent
tolerability, minimal toxicity, affordability, self-administerability, and
sufficiently strong evidence of efficacy to be actionable, in the here and now.
We conclude with a call to action to promote and nurture additional study into
the wide range of advantages of melatonin and to support its wise application
within the current therapeutic environment.
Author(s) Details:
Constantine Kaniklidis,
No Surrender Breast Cancer Foundation (NSBCF), USA.
Please see the link here: https://stm.bookpi.org/CPMS-V5/article/view/7655
No comments:
Post a Comment